Pharmacokinetics of Abt-493 and Abt-530 given alone or in combination in Healthy Caucasian, Chinese, and Japanese Adult Subjects

Trial Profile

Pharmacokinetics of Abt-493 and Abt-530 given alone or in combination in Healthy Caucasian, Chinese, and Japanese Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 11 Aug 2017 Results of this and one another phase I study published in the Journal of Clinical Pharmacology.
    • 07 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top